To assess the clinical significance of PCSK9 as a candidate biomarker, we measured the protein level of PCSK9 in NTD maternal serum and control maternal serum at different gestational ages (15–20 w, 23–27 w, and 37–40 w). Here, PCSK9 is linked to neural tube defect.